Equillium to present data supporting CD6-ALCAM at ASH annual meet
Category: #health  By Nikita Chaurasia  Date: 2019-11-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

Equillium to present data supporting CD6-ALCAM at ASH annual meet

Equillium Inc., a clinical-stage biotechnology company, has reportedly announced that it will be presenting positive data related to the role CD6-ALCAM pathway as a relevant target for patients who are suffering from acute graft versus host disease (aGVHD). The company will also be presenting the details of its EQUATE Phase 1b/2 clinical trial design at 61st ASH Annual Meeting, which will be held in Orlando, Florida.

Reportedly, the data representing itolizumab inhibits T cell responses in aGVHD positive patients’ sample. Moreover, it favors itolizumab as a possible systemic therapy which can regulate pathogenic T effector cell activity in an in vivo disease model.

Dr. Jerome Ritz, Exec Director of CMCF at the Dana-Farber Cancer Institute and Prof. of Medicine at Harvard Medical School, said that around 30-70 percent of patients who receive allogeneic HSCT along with standard GVHD prophylaxis regimens are identified with aGVHD. This disorder is a leading cause of non-relapse mortality in patients undergoing allogeneic HSCT. However, there are no approved treatments available for this disease yet. 

Ritz added that they would further research on EQUATE trial. With Dr. Robert Soiffer, he has conducted a study at Dana-Farber over a decade ago that clarified the role of CD6+ T effector cells in the development of aGVHD.

As per Stephen Connelly, Ph.D., Chief Scientific Officer, Equillium, these data show the potential of CD6 blockade to inhibit T effector cell responses, which further supported the company’s ongoing EQUATE Phase 1b/2 clinical trial of itolizumab for front-line treatment in patients who are suffering from aGVHD.

He added that the EQUATE trial is designed to determine the activity and safety of itolizumab. The company is looking forward to sharing positive translational data and study design at ASH Annual Meeting and Exposition and offer future updates of its programs as they progress. 

Source Credit - https://ir.equilliumbio.com/news-releases/news-release-details/equillium-present-translational-data-itolizumab-acute-graft

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Emirates could slash 30,000 jobs to lower cost during COVID-19 crisis
Emirates could slash 30,000 jobs to lower cost during COVID-19 crisis
By Nikita Chaurasia

Emirates Group has reportedly been planning to lay off around 30,000 jobs in order to lower the cost amid the pandemic outbreak, that will soon bring the total number of employees working by nearly 30% from over 105,000 close to March-end. Apparentl...

Apple acquires live event recording and VR broadcaster NextVR
Apple acquires live event recording and VR broadcaster NextVR
By Nikita Chaurasia

Apple has recently confirmed that it has acquired NextVR, which is a virtual reality startup that specializes in recording live events such as sports matches and concerts for  VR experience. The announcement made by the company came after the pu...

Grant worth $6mn introduced in Singapore to support FinTech companies
Grant worth $6mn introduced in Singapore to support FinTech companies
By Nikita Chaurasia

The recent coronavirus pandemic has largely affected umpteen businesses globally. In a bid to help Fintech companies meet their day-to-day expenses, the Monetary Authority of Singapore (MAS), has established the FinTech Solidarity Grant that would pr...